Yan Pan

Yan Pan

Auto-generated profile, based on publicly available information

Yan Pan

Key Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, School of Basic Medical Sciences and Department of Physiology, Nanjing Medical University, Jiangsu, China (R.H., J.B., Y.P., C.L., A. Chen, Y.H.).

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
CBChanglei Bao
Changlei Bao
QHQian He
Qian He
HWHui Wang
Hui Wang
YSYanan Sun
Yanan Sun
YXYahang Xu
Yahang Xu
HYHan Ying
Han Ying
Background. Pulmonary arterial hypertension (PAH) is a complex pulmonary vasculature disease characterized by progressive obliteration of small pulmonary arteries and persistent increase in pulmonary vascular resistance, resulting in right heart failure and death if left untreated. Artemisinin (ARS) and its derivatives, which are common antimalarial drugs, have been found to possess a broad range of biological effects. Here, we sought to determine the therapeutic benefit and mechanism of ARS and its derivatives treatment in experimental pulmonary hypertension (PH) models. Methods. Isolated perfused/ventilated lung and isometric tension measurements in arteries were performed to test pulmonary vasoconstriction and relaxation. Monocrotaline (MCT) and hypoxia+Su5416 (SuHx) were administered to rats to induce severe PH. Evaluation methods of ARS treatment and its derivatives in animal models include echocardiography, hemodynamics measurement, and histological staining. In vitro, the effect of these drugs on proliferation, viability, and hypoxia‐inducible factor 1α (HIF1α) was examined in human pulmonary arterial smooth muscle cells (hPASMCs). Results. ARS treatment attenuated pulmonary vasoconstriction induced by high K+ solution or alveolar hypoxia, decreased pulmonary artery (PA) basal vascular tension, improved acetylcholine‐ (ACh‐) induced endothelial‐dependent relaxation, increased endothelial nitric oxide (NO) synthase (eNOS) activity and NO levels, and decreased levels of NAD(P)H oxidase subunits (NOX2 and NOX4) expression, NAD(P)H oxidase activity, and reactive oxygen species (ROS) levels of pulmonary arteries (PAs) in MCT‐PH rats. NOS inhibitor, L‐NAME, abrogated the effects of ARS on PA constriction and relaxation. Furthermore, chronic application of both ARS and its derivative dihydroartemisinin (DHA) attenuated right ventricular systolic pressure (RVSP), Fulton index (right ventricular hypertrophy), and vascular remodeling of PAs in the two rat PH models. In addition, DHA inhibited proliferation and migration of hypoxia‐induced PASMCs. Conclusions. In conclusion, these results indicate that treatment with ARS or DHA can inhibit PA vasoconstriction, PASMC proliferation and migration, and vascular remodeling, as well as improve PA endothelium‐dependent relaxation, and eventually attenuate the development and progression of PH. These effects might be achieved by decreasing NAD(P)H oxidase generated ROS production and increasing eNOS activation to release NO in PAs. ARS and its derivatives might have the potential to be novel drugs for the treatment of PH.

1 July 2026 in Hypertension
Verified
Journal Article
Closed access
RHRuihua Hu
Ruihua Hu
JBJie Bai
Jie Bai
YPYan Pan
Yan Pan
DLDingyuan Liu
Dingyuan Liu
CLCaiyu Li
Caiyu Li
HYHan Ying
Han Ying
BACKGROUND: A hallmark of pulmonary hypertension (PH) is the progressive increase in pulmonary arterial resistance caused by impaired pulmonary artery (PA) relaxation and vascular remodeling. Salusin-α, a cardiovascular-active peptide, has been implicated in several cardiovascular diseases; however, its role in PH remains undefined. METHODS: PAs were isolated from rats for isometric tension recording to assess relaxation. PA remodeling was quantified using histological morphometric analysis. Right ventricular pressure and hypertrophy were measured to evaluate PH severity. RESULTS: Salusin-α levels were significantly decreased in both plasma and PAs from PH rats compared with controls. Both acute and chronic salusin-α administration improved endothelium-dependent and -independent PA relaxation, increased endothelial nitric oxide synthase activity and nitric oxide levels in PA endothelial cells, enhanced Nrf2 (nuclear factor erythroid 2-related factor 2) and superoxide dismutase expression and activity in PA smooth muscle cells, and decreased NAD(P)H oxidase expression, activity, and reactive oxygen species levels. Salusin-α also inhibited PA smooth muscle cell proliferation and migration, attenuated pulmonary vascular remodeling, and decreased right ventricular pressure, hypertrophy, and mortality in PH rats. Neutralizing endogenous salusin-α exerted opposite effects. Pharmacological inhibition demonstrated that endothelial nitric oxide synthase and superoxide dismutase contributed to the protective actions of salusin-α, whereas NAD(P)H oxidase inhibition or reactive oxygen species scavenging prevented the effects of salusin-α neutralization. CONCLUSIONS: Salusin-α improves endothelium-dependent vasodilation via endothelial nitric oxide synthase mediated nitric oxide release in PA endothelial cells, and promotes endothelium-independent vasodilation while attenuating pulmonary vascular remodeling via inhibition of NAD(P)H oxidase-reactive oxygen species signaling and activation of the Nrf2/superoxide dismutase signaling. Restoring reduced salusin-α may present a novel therapeutic strategy for PH treatment.

24 March 2026 in Precision Medical Sciences
Verified
Journal Article
Open access
LDLi Dai
Li Dai
MCMosi Chen
Mosi Chen
JHJun Hu
Jun Hu
LHLei Huang
Lei Huang
YYYe Yang
Ye Yang
BQBingjun Qian
Bingjun Qian
Coronary artery disease (CAD) is characterized by significant genetic diversity with interindividual genetic variation. Genomewide association studies have discovered many CAD‐associated single‐nucleotide polymorphisms (SNPs) and provided for the development of polygenic risk scores (PRS) to measure total genetic susceptibility. This review reviews the present evidence of SNPs in connection with CAD risk, discusses biological mechanisms whereby genetic variation affects vascular and metabolic phenotypes, and provides some methodological advances and limitations in PRS construction and testing. Although PRS extends risk stratification beyond clinical factors, its clinical utility is limited by population‐level effects, limited biological interpretability, and variable predictive performance. Furthermore, we also discuss new approaches incorporating genetically informed risk assessment into clinical and imaging‐based schemes to aid precision prevention. By explicitly bridging genetic association, biological interpretabilities, and clinical support, we aim to encourage responsible translation of genetic risk stratifying into CAD prevention.